UiPath, Inc. (PATH)

UiPath, Inc. (PATH) is trading at $12.83, down 1.16% in the last session, and sits between its 200-day average ($12.33), which it holds above, and its 50-day average ($13.71), which it sits below. The stock is 35.33% below its 52-week high of $19.84 and 39.46% above its 52-week low of $9.20. The near-term story is one of cooling sentiment: DA Davidson downgraded the stock to Underperform from Neutral on September 28, 2026, and the stock has fallen 4.82% over the past month and 18.38% over three months. Against that, the business is growing revenue, earns a net profit margin of 21.03%, and trades at a P/E of 19.15, a discount to the sector median of 35.1.

The most visible recent event is DA Davidson's downgrade of UiPath to Underperform from Neutral on September 28, 2026. It came days after a cluster of holds from other brokers: UBS kept its Neutral rating on September 25, BMO Capital kept its Market Perform rating on September 24, Canaccord Genuity and TD Cowen each kept their Hold ratings on September 24, and Truist Securities kept its Hold rating on September 23. The consensus rating is Hold, with 3 buy or strong buy ratings, 15 holds and 2 sell or strong sell ratings out of 20. Three months earlier the split was 3 buys out of 20, so the buy count has not moved, but the sell side now includes a firm that was previously neutral.

The September 3, 2026 report delivered EPS of $0.15, exactly matching the analysts' estimate, and the stock fell 16.63% in the first trading session afterwards. The May 28, 2026 report was a small miss, with EPS of $0.15 against $0.16 expected, and the stock rose 1.21% the next session. Across the last eight reports, six beat the EPS estimate, yet three of those beats were followed by a lower share price in the first session. The record shows that meeting or beating the EPS estimate has not reliably moved the stock on its own, and investors appear to be focused on growth and guidance.

PATH trades at a P/E of 19.15, which is 45.4% below the sector median of 35.1, and its price-to-sales ratio of 3.89 is 48.8% below the sector median of 7.6. Its return on equity of 20.03% is above the sector median of 13.4%, and its debt-to-equity ratio is 0.04. The low multiples reflect that gap in growth. Market capitalisation is $6.7B, and the stock has a beta of 1.04 against the S&P 500 with a typical daily move of 2.32%.

Insiders sold stock worth $169.4M over the last 18 months across 126 sales, and made no open-market purchases in that period. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market buying.

The base case is that PATH keeps trading in the range between its 200-day average and its 50-day average while the market weighs slower top-line growth against a low valuation. Revenue grew 13.40% in the latest quarter, year on year, which is 10.8 percentage points slower than the sector median of 24.2%, and analysts expect revenue to grow 11.3% this fiscal year and EPS to grow 9.4%. For the bullish case to take hold, the price would need to reclaim the 50-day average at $13.71 and the 20-day EMA at $13.38, and revenue growth would need to accelerate toward the sector pace. The analysts' median 12-month target is $15.00, with a range from $10.00 to $23.00. Three of the 20 analysts rate the stock buy or strong buy, 15 hold it, and two sell it.

Support sits first at the 200-day simple moving average of $12.33, the nearest level below the price, which the stock is currently holding above. Below that is the 52-week low of $9.20, the next level a further fall would meet. Resistance sits first at the 20-day exponential moving average of $13.38, the nearest level above the price, followed by the 50-day simple moving average of $13.71. The 52-week high of $19.84 is the furthest level above the price and would be reached only after a sustained recovery through the averages.